View Financial HealthGrifols 배당 및 자사주 매입배당 기준 점검 3/6Grifols 수익으로 충분히 충당되는 현재 수익률 3.34% 보유한 배당금 지급 회사입니다.핵심 정보3.3%배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률4.6%배당 성장률-2.6%다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향33%최근 배당 및 자사주 매입 업데이트Upcoming Dividend • Aug 04Upcoming dividend of €0.12 per shareEligible shareholders must have bought the stock before 11 August 2025. Payment date: 13 August 2025. The company last paid an ordinary dividend in October 2014. The average dividend yield among industry peers is 2.1%.모든 업데이트 보기Recent updatesValuation Update With 7 Day Price Move • Jun 01Investor sentiment improves as stock rises 17%After last week's 17% share price gain to €10.32, the stock trades at a forward P/E ratio of 11x. Average trailing P/E is 16x in the Biotechs industry in Europe. Total loss to shareholders of 10% over the past three years.공시 • May 18Grifols, S.A., Annual General Meeting, Jun 17, 2026Grifols, S.A., Annual General Meeting, Jun 17, 2026. Location: parque empresarial can sant joan, avinguda de la generalitat, sant cugat del valles, barcelona., SpainReported Earnings • May 11First quarter 2026 earnings releasedFirst quarter 2026 results: EPS: €0.11. Revenue: €1.70b (down 4.8% from 1Q 2025). Net income: €73.0m (up 22% from 1Q 2025). Profit margin: 4.3% (up from 3.3% in 1Q 2025). Revenue is forecast to grow 5.7% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 77% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.공시 • Feb 25Grifols, S.A. to Report Fiscal Year 2025 Results on Feb 26, 2026Grifols, S.A. announced that they will report fiscal year 2025 results at 5:35 PM, Central European Standard Time on Feb 26, 2026Valuation Update With 7 Day Price Move • Feb 03Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to €9.98, the stock trades at a forward P/E ratio of 14x. Average trailing P/E is 17x in the Biotechs industry in Europe. Total loss to shareholders of 25% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €18.75 per share.공시 • Jan 09Grifols, S.A. Announces Board Changes, Effective January 1, 2026Grifols, S.A. Board of Directors resolved to unanimously approve, with effect from January 1, 2026, the appointment of Ms. Laura de la Cruz Galán as the new Secretary non-member of the Board of Directors, replacing Mrs. Núria Martín Barnés, and the appointment of Mrs. Núria Martín Barnés as the new Vice-secretary non-member of the Board of Directors, replacing Ms. Laura de la Cruz Galán.Valuation Update With 7 Day Price Move • Dec 18Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €11.85, the stock trades at a forward P/E ratio of 14x. Average trailing P/E is 17x in the Biotechs industry in Europe. Total returns to shareholders of 12% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €21.17 per share.New Risk • Dec 14New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 2.8x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.8x net interest cover). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (6.7% average weekly change).New Risk • Nov 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 5.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (5.9% average weekly change).Valuation Update With 7 Day Price Move • Nov 24Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to €9.33, the stock trades at a forward P/E ratio of 13x. Average trailing P/E is 18x in the Biotechs industry in Europe. Total loss to shareholders of 7.8% over the past three years.Upcoming Dividend • Aug 04Upcoming dividend of €0.12 per shareEligible shareholders must have bought the stock before 11 August 2025. Payment date: 13 August 2025. The company last paid an ordinary dividend in October 2014. The average dividend yield among industry peers is 2.1%.New Risk • Jul 31New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 3.0x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (3.0x net interest cover). Minor Risks Share price has been volatile over the past 3 months (5.5% average weekly change). Large one-off items impacting financial results.Reported Earnings • Jul 30Second quarter 2025 earnings releasedSecond quarter 2025 results: Revenue: €1.89b (up 4.0% from 2Q 2024). Net income: €117.1m (up €102.2m from 2Q 2024). Profit margin: 6.2% (up from 0.8% in 2Q 2024). Revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Europe.Board Change • Jun 25High number of new directorsIndependent Director Pascal Ravery was the last director to join the board, commencing their role in 2024.공시 • May 12Grifols, S.A. to Report Q1, 2025 Results on May 12, 2025Grifols, S.A. announced that they will report Q1, 2025 results on May 12, 2025공시 • May 03Grifols, S.A., Annual General Meeting, Jun 04, 2025Grifols, S.A., Annual General Meeting, Jun 04, 2025. Location: parque empresarial can sant joan, avinguda de la generalitat, 152-158, 08174 sant cugat del valles, barcelona SpainValuation Update With 7 Day Price Move • Apr 04Investor sentiment deteriorates as stock falls 21%After last week's 21% share price decline to €8.18, the stock trades at a forward P/E ratio of 12x. Average trailing P/E is 21x in the Biotechs industry in Europe. Total loss to shareholders of 50% over the past three years.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 1GRF 의 배당금 지급은 지난 10 년 동안 휘발성이었습니다.배당금 증가: 1GRF 의 배당금 지급액은 지난 10 년 동안 증가하지 않았습니다.배당 수익률 vs 시장Grifols 배당 수익률 vs 시장1GRF의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (1GRF)3.3%시장 하위 25% (IT)1.6%시장 상위 25% (IT)4.8%업계 평균 (Biotechs)2.4%분석가 예측 (1GRF) (최대 3년)4.6%주목할만한 배당금: 1GRF 의 배당금( 3.34% )은 Italian 시장에서 배당금 지급자의 하위 25%( 1.6% )보다 높습니다.고배당: 1GRF 의 배당금( 3.34% )은 Italian 시장에서 배당금 지급자의 상위 25%( 4.81% )와 비교해 낮습니다.주주 대상 이익 배당수익 보장: 합리적으로 낮은 지불 비율 ( 33.1% )로 1GRF 의 배당금 지급은 수익으로 충분히 충당됩니다.주주 현금 배당현금 흐름 범위: 합리적으로 낮은 현금 지급 비율 ( 34.3% )로 1GRF 의 배당금 지급은 현금 흐름으로 잘 충당됩니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YIT 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/08 21:05종가2026/06/08 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Grifols, S.A.는 29명의 분석가가 다루고 있습니다. 이 중 11명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관null nullBanco de Sabadell. S.A.Luis ArredondoBanco de Sabadell. S.A.Jaime EscribanoBanco Santander26명의 분석가 더 보기
Upcoming Dividend • Aug 04Upcoming dividend of €0.12 per shareEligible shareholders must have bought the stock before 11 August 2025. Payment date: 13 August 2025. The company last paid an ordinary dividend in October 2014. The average dividend yield among industry peers is 2.1%.
Valuation Update With 7 Day Price Move • Jun 01Investor sentiment improves as stock rises 17%After last week's 17% share price gain to €10.32, the stock trades at a forward P/E ratio of 11x. Average trailing P/E is 16x in the Biotechs industry in Europe. Total loss to shareholders of 10% over the past three years.
공시 • May 18Grifols, S.A., Annual General Meeting, Jun 17, 2026Grifols, S.A., Annual General Meeting, Jun 17, 2026. Location: parque empresarial can sant joan, avinguda de la generalitat, sant cugat del valles, barcelona., Spain
Reported Earnings • May 11First quarter 2026 earnings releasedFirst quarter 2026 results: EPS: €0.11. Revenue: €1.70b (down 4.8% from 1Q 2025). Net income: €73.0m (up 22% from 1Q 2025). Profit margin: 4.3% (up from 3.3% in 1Q 2025). Revenue is forecast to grow 5.7% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 77% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.
공시 • Feb 25Grifols, S.A. to Report Fiscal Year 2025 Results on Feb 26, 2026Grifols, S.A. announced that they will report fiscal year 2025 results at 5:35 PM, Central European Standard Time on Feb 26, 2026
Valuation Update With 7 Day Price Move • Feb 03Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to €9.98, the stock trades at a forward P/E ratio of 14x. Average trailing P/E is 17x in the Biotechs industry in Europe. Total loss to shareholders of 25% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €18.75 per share.
공시 • Jan 09Grifols, S.A. Announces Board Changes, Effective January 1, 2026Grifols, S.A. Board of Directors resolved to unanimously approve, with effect from January 1, 2026, the appointment of Ms. Laura de la Cruz Galán as the new Secretary non-member of the Board of Directors, replacing Mrs. Núria Martín Barnés, and the appointment of Mrs. Núria Martín Barnés as the new Vice-secretary non-member of the Board of Directors, replacing Ms. Laura de la Cruz Galán.
Valuation Update With 7 Day Price Move • Dec 18Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €11.85, the stock trades at a forward P/E ratio of 14x. Average trailing P/E is 17x in the Biotechs industry in Europe. Total returns to shareholders of 12% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €21.17 per share.
New Risk • Dec 14New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 2.8x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.8x net interest cover). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (6.7% average weekly change).
New Risk • Nov 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 5.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (5.9% average weekly change).
Valuation Update With 7 Day Price Move • Nov 24Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to €9.33, the stock trades at a forward P/E ratio of 13x. Average trailing P/E is 18x in the Biotechs industry in Europe. Total loss to shareholders of 7.8% over the past three years.
Upcoming Dividend • Aug 04Upcoming dividend of €0.12 per shareEligible shareholders must have bought the stock before 11 August 2025. Payment date: 13 August 2025. The company last paid an ordinary dividend in October 2014. The average dividend yield among industry peers is 2.1%.
New Risk • Jul 31New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 3.0x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (3.0x net interest cover). Minor Risks Share price has been volatile over the past 3 months (5.5% average weekly change). Large one-off items impacting financial results.
Reported Earnings • Jul 30Second quarter 2025 earnings releasedSecond quarter 2025 results: Revenue: €1.89b (up 4.0% from 2Q 2024). Net income: €117.1m (up €102.2m from 2Q 2024). Profit margin: 6.2% (up from 0.8% in 2Q 2024). Revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Europe.
Board Change • Jun 25High number of new directorsIndependent Director Pascal Ravery was the last director to join the board, commencing their role in 2024.
공시 • May 12Grifols, S.A. to Report Q1, 2025 Results on May 12, 2025Grifols, S.A. announced that they will report Q1, 2025 results on May 12, 2025
공시 • May 03Grifols, S.A., Annual General Meeting, Jun 04, 2025Grifols, S.A., Annual General Meeting, Jun 04, 2025. Location: parque empresarial can sant joan, avinguda de la generalitat, 152-158, 08174 sant cugat del valles, barcelona Spain
Valuation Update With 7 Day Price Move • Apr 04Investor sentiment deteriorates as stock falls 21%After last week's 21% share price decline to €8.18, the stock trades at a forward P/E ratio of 12x. Average trailing P/E is 21x in the Biotechs industry in Europe. Total loss to shareholders of 50% over the past three years.